A landmark investigation led by researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai has significantly redefined the understanding of Phelan-McDermid syndrome (PMS), indicating that this neurodevelopmental condition may affect a considerably larger population than previously estimated. The comprehensive findings, recently disseminated in the journal Autism Research, suggest that approximately one in every 7,300 individuals lives with PMS, a figure that represents a substantial departure from earlier, more conservative projections. This revised prevalence estimate carries profound implications for diagnostic strategies, therapeutic development, and patient advocacy, highlighting an urgent need for broader genetic screening.
Phelan-McDermid syndrome is a complex genetic disorder characterized by a specific anomaly on chromosome 22. It arises from either a deletion of the terminal end of the long arm of chromosome 22 (22q13.3) or a pathogenic mutation within the SHANK3 gene, which resides in this critical region. The SHANK3 gene plays a pivotal role in the proper development and function of synapses, the connections between neurons in the brain. Its protein product is essential for synaptic plasticity, learning, and memory. Consequently, disruptions to SHANK3 can precipitate a wide array of neurological, developmental, and behavioral challenges. Individuals diagnosed with PMS frequently exhibit global developmental delays, intellectual disability ranging from moderate to severe, significant speech and language impairments, and motor deficits such as hypotonia (low muscle tone) and coordination difficulties. Behavioral manifestations are also common, with a substantial majority meeting the diagnostic criteria for autism spectrum disorder (ASD). Indeed, alterations in the SHANK3 gene are recognized as a notable monogenic cause of autism, potentially accounting for up to one percent of all ASD cases. Beyond these core symptoms, associated medical issues can include epilepsy, sleep disturbances, gastrointestinal problems, and distinctive physical features, though these vary widely among affected individuals.
The challenge of accurately estimating the prevalence of rare genetic conditions like PMS is considerable, often hampered by a lack of widespread awareness among clinicians, inconsistent diagnostic practices, and limitations in genetic testing accessibility. To overcome these obstacles, the Mount Sinai research team embarked on an ambitious, multi-institutional collaborative effort. Their methodology involved an extensive review of genetic data drawn from nearly 180,000 individuals diagnosed with autism who had undergone various forms of genetic analysis. This vast dataset was meticulously compiled from ten distinct sources, encompassing leading commercial genetic testing laboratories such as GeneDx, Labcorp, and Ambry Genetics, major academic medical centers, and prominent autism research initiatives including the SPARK research study and the Autism Sequencing Consortium. By aggregating and scrutinizing such a diverse and large volume of genetic information, the researchers aimed to construct a more robust and representative picture of PMS occurrence.
Crucially, the study’s analytical framework extended beyond simply counting confirmed diagnoses. The researchers employed sophisticated statistical models to account for several critical variables that could influence prevalence estimates. These adjustments included an allowance for individuals with PMS who might not yet have received a formal genetic diagnosis, an acknowledgment of the varying sensitivities and specificities of different genetic testing platforms, and a consideration for those individuals living with Phelan-McDermid syndrome who do not explicitly meet the criteria for autism spectrum disorder, thereby expanding the scope beyond an ASD-centric analysis. After these comprehensive adjustments, the team arrived at an estimated prevalence of 13.7 cases per 100,000 people, which translates to approximately 1 in 7,300 individuals. This groundbreaking estimate suggests that in the United States alone, potentially more than 45,000 individuals could be affected by Phelan-McDermid syndrome, a number far exceeding previous assumptions and underscoring a significant diagnostic gap.
Tess Levy, MSc, an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the primary author of the research paper, highlighted the likely reasons for this substantial discrepancy between known and estimated cases. "The considerable disparity between identified and projected cases is largely attributable to the fact that a significant number of individuals presenting with developmental disabilities and autism are never offered genetic evaluation," Levy explained. "Families frequently encounter hurdles related to insurance coverage or may receive genetic tests that do not adequately assess the SHANK3 gene, leading to missed diagnoses."
The revelations from this study arrive at a critical juncture for the Phelan-McDermid syndrome community, coinciding with a period of rapid advancement in therapeutic research. Several precision medicine approaches, specifically designed to target the underlying biological mechanisms of the disorder, are currently progressing through various stages of clinical trials. For individuals and their families grappling with developmental challenges, obtaining a definitive genetic diagnosis transcends mere symptomatic understanding. It unlocks a crucial pathway to specialized medical management tailored to the specific genetic etiology, facilitates participation in cutting-edge research studies and clinical trials, provides access to invaluable patient support networks, and offers the potential for future disease-modifying treatments.
Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the publication, passionately advocated for universal genetic screening. "We strongly advocate that every child diagnosed with autism undergo comprehensive genetic testing, as accurate genetic information empowers us," Dr. Buxbaum stated. "These genetic insights are indispensable for researchers to design more precise and targeted clinical trials for potential interventions. I am genuinely optimistic that within the next five years, we will witness successful therapeutic breakthroughs stemming directly from these genetic discoveries."
The study received vital support from CureSHANK, a leading patient advocacy organization, and Neuren Pharmaceuticals, a biotechnology company actively involved in developing treatments for neurodevelopmental disorders. Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, emphasized the ethical imperative underpinning this research. "Neuren Pharmaceuticals initiated this pivotal PMS prevalence study in partnership with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments nearing reality, identifying these individuals has become an ethical mandate. Patients cannot reap the benefits of these scientific advancements if they remain undiagnosed." This sentiment was echoed by Geraldine Bliss, Board Chair of CureSHANK, who affirmed, "This research validates what many families, clinicians, and advocates have long suspected. There are likely tens of thousands of individuals living with Phelan-McDermid syndrome who have yet to receive a genetic diagnosis. In an era where multiple therapeutic candidates are advancing into clinical trials, locating these individuals has never been more urgent."
The findings reinforce CureSHANK’s ongoing commitment to expanding access to genetic testing and align seamlessly with the objectives of the "Start Genetic" campaign. This global awareness initiative actively encourages patients, families, healthcare providers, and advocacy groups to prioritize genetic considerations in the diagnostic process. The broader, overarching message is clear: the promise of precision medicine, with its potential for highly individualized and effective treatments, can only be fully realized when patients are accurately identified and diagnosed at the earliest possible stage. This new understanding of Phelan-McDermid syndrome’s prevalence is not merely a statistical adjustment; it is a catalyst for renewed action, driving a collective push towards comprehensive genetic screening and accelerating the journey from scientific discovery to tangible patient benefit.
About the Author
